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![AKT-specific inhibitor MK2206 decreases cell viability, spheroid formation, and migration of SETD2 deficient ccRCC-derived cells.\
(**A**) Bright-field microscopy images showing living cells (attached to bottom of well) stained with 0.3% crystal violet solution of *SETD2* (+/+) 786-0 and *SETD2* (KO) 786-0 and (--/--) A498 cells were treated with vehicle (DMSO) or 1 μM AKT-specific inhibitor MK2206 for 10 days. (**B**) Bar graph showing relative cell viability as a percentage of CTL of *SETD2* (+/+) 786-0 and *SETD2* (KO) 786-0 and (--/--) A498 cells in response to treatment with MK2206. \*\*\*\*P \< 0.0001; ns, no statistical significance observed. Standard deviations were calculated and represented for all conditions. (**C**) Phase-contrast pictures showing spheroid formation of SETD2 (+/+) 786-0 and *SETD2* (KO) 786-0 and (--/--) A498 cells in response to treatment with vehicle (DMSO) and 500 nM inhibitor for 14 days grown in Matrigel. (**D**) Bar graph showing average colony number of *SETD2* (+/+) 786-0 and *SETD2* (KO) 786-0 and (--/--) A498 cells treated with MK2206 inhibitor. \*\*\*\*P \< 0.0001; ns, no statistical significance observed. Standard deviations were calculated and represented for all conditions. (**E**) Bright-field microscopy images showing living cells stained with 0.3% crystal violet solution. (**F**) Bar graph showing percentage (%) of wound closure compared to cells treated with vehicle (DMSO). (**G**) Western blot analysis of indicated proteins showing variations in phosphorylation levels in response to chemical inhibition with MK2206 (AKT-specific). Whole-cell protein lysates from cells treated with 1 μM inhibitor for 24 hours were resolved by SDS-PAGE. Actin is a loading control.](oncotarget-10-6391-g001){#F1}
